In 1995, at Moorfields Eye Hospital London — in Fred Fitzke's laboratory, under the scientific direction of Alan Bird — Andrea von Rückmann developed a new diagnostic method as first author: fundus autofluorescence.
The method revolutionised the diagnosis of macular disease and has since been used in more than 2'000 scientific studies worldwide. Today it is a diagnostic standard in specialised eye centres: new therapies against dry macular degeneration must prove their effect with this method — the American regulator FDA formally recognised it as a measurement instrument in 2023. Current gene therapies, the newest class of treatments in ophthalmology, measure their success with it.
A discovery from 1995 — still the measure of every advance in ophthalmology. That is the standard by which Andrea von Rückmann practises medicine. In research. In surgery. And in every conversation with her patients.